 |
12 Diseases |  |
1 Trial |
|
1 Trial |  |
217 News |  |
| «123 |
- |||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarzio (filgrastim biosimilar) / Novartis
Clinical: Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=55, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change: Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 29, 2013
P2, N=180, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=102 --> 180
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz, Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial initiation date: Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2013
P1/2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
N=102 --> 180 Initiation date: Oct 2013 --> May 2014
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarzio (filgrastim biosimilar) / Novartis
Clinical: Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 17, 2013
P1/2, N=55, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||||| Zarxio (filgrastim-sndz) / Sandoz
Trial completion: PIONEER: Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim (clinicaltrials.gov) - Jul 16, 2013
P3, N=218, Completed, Sponsor: Sandoz
Initiation date: Oct 2013 --> May 2014 Recruiting --> Completed
- | Zarxio (filgrastim-sndz) / Sandoz
New P4 trial: Immunogenicity, Safety, and Efficacy of Zarzio (clinicaltrials.gov) - May 20, 2013
P4, N=40, Recruiting, Sponsor: Sandoz
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Zarxio (filgrastim-sndz) / Sandoz, Starasid (cytarabine ocfosfate) / Nippon Kayaku
New P1/2 trial: Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 6, 2013
P1/2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Zarzio (filgrastim biosimilar) / Novartis
Clinical: SMART: Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors (clinicaltrials.gov) - Jan 9, 2013
P=N/A, N=200, Recruiting, Sponsor: Sandoz
- |||||||||| Zarxio (filgrastim-sndz) / Sandoz
New P3 trial: PIONEER: Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim (clinicaltrials.gov) - Jan 12, 2012
P3, N=218, Completed, Sponsor: Sandoz
- ||| Zarxio (filgrastim-sndz) / Novartis
Clinical data: Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (clinicaltrials.gov) - Aug 29, 2011
P=N/A, N=1500, Recruiting, Sponsor: Sandoz